Antigen News and Research

RSS

Research roundup: Unraveling why elderly men are tested for prostate cancer; Difficulty paying medical bills

Medical Center Characteristics Associated With PSA Screenings In Elderly Veterans With Limited Life Expectancy -- Medical guidelines recommend against prostate-specific antigen (PSA) screenings for prostate cancer in men with limited life expectancy, but studies have shown that many elderly men still get the test.

23 Dec 2011

Researchers present results from 31 major studies of blood-related cancers at ASH 2011 meeting

Researchers from the John Theurer Cancer Center at Hackensack University Medical Center, one of the nation's top 50 best hospitals for cancer, presented results from 31 major studies of blood-related cancers - leukemia, lymphoma and multiple myeloma -- during the American Society of Hematology (ASH) Annual Meeting, December 10-13, 2011 in San Diego.

23 Dec 2011

Malaria vaccine shows early success

An experimental vaccine for malaria has been developed by British scientists. It has shown early potential to neutralize many, perhaps all, strains of the deadliest malaria parasite.

21 Dec 2011

University of Western Ontario receives FDA approval to begin SAV001 HIV trial

The first and only preventative HIV vaccine based on a genetically modified killed whole virus has received approval by the United States Food and Drug Administration (FDA) to start human clinical trials.

21 Dec 2011

Study assesses evidence of immunosuppression in sepsis

An analysis of lung and spleen tissue from patients who died of sepsis revealed certain biochemical, cellular and histological findings that were consistent with immunosuppression, according to a study in the December 21 issue of JAMA.

21 Dec 2011

UCB initiates EXXELERATE study in rheumatoid arthritis

UCB today announced the start of the EXXELERATE study which will evaluate the short- and long-term efficacy of Cimzia (certolizumab pegol) plus methotrexate (MTX) compared with that of Humira(adalimumab) plus MTX in the treatment of moderate to severe rheumatoid arthritis (RA). The start of this study confirms previously announced plans.

21 Dec 2011

University of Oxford scientists develop new candidate malaria vaccine

A new candidate malaria vaccine with the potential to neutralise all strains of the most deadly species of malaria parasite has been developed by a team led by scientists at the University of Oxford.

21 Dec 2011

Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

Generex Biotechnology Corporation today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 Dec 2011

Delaware Court upholds original ruling in favor of PharmAthene

PharmAthene, Inc. today announced that the Delaware Court of Chancery has denied SIGA Technologies' motion for reargument filed on October 4, 2011, upholding the Court's original September 22, 2011 decision awarding PharmAthene 50% of the net profits over ten years from all sales of SIGA's smallpox antiviral therapeutic, ST-246, and related products, after SIGA receives the first $40 million in net profits.

19 Dec 2011

Soligenix secures Harvard option rights to initiate anthrax vaccine development program

Soligenix, Inc., a development stage biopharmaceutical company, announced today that it has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein.

16 Dec 2011

FIND, NUS collaborate to identify novel biomarkers for TB diagnosis

A research team from the National University of Singapore (NUS) Singapore Lipidomics Incubator (SLING) is collaborating with the Foundation for Innovative New Diagnostics (FIND) to identify novel target molecules to be employed as biomarkers for the detection of active tuberculosis.

15 Dec 2011

JHN to initiate new Phase I immunotherapy trial in glioblastoma

Physicians at the Jefferson Hospital for Neuroscience (JHN), the region's only dedicated hospital for neuroscience, are tackling a particularly aggressive brain cancer that even surgery, chemotherapy and radiation often fail to treat with a promising new immunotherapy to attack a patient's tumor with their own cancer cells.

15 Dec 2011

Fresh cells can pep talk immune cells exhausted by HIV or hepatitis C

Chronic infections by viruses such as HIV or hepatitis C eventually take hold because they wear the immune system out, a phenomenon immunologists describe as exhaustion.

14 Dec 2011

Celgene announces data from REVLIMID Phase III study on high-risk asymptomatic smoldering MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, announced that updated data evaluating continuous treatment with REVLIMID (lenalidomide) in patients with high-risk asymptomatic smoldering multiple myeloma were presented at the 53rd Annual Meeting of the American Society of Hematology.

14 Dec 2011

NYUCI experts present latest research findings about hematologic cancers at 53rd ASH meeting

Experts from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, presented their latest research findings about hematologic cancers at the 53rd ASH Annual Meeting and Exposition held December 10-13, 2011 in San Diego, California.

14 Dec 2011

ImmusanT secures $20M in Series A financing

ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2, companion diagnostic and monitoring tool for celiac disease.

14 Dec 2011

Research describes advantages of new vaccine adjuvant

New research from the laboratory of Dr. Elizabeth Leadbetter at the Trudeau Institute may lead to a whole new class of vaccines. Dr. Leadbetter's lab has discovered new properties of a potential vaccine adjuvant that suggest it could be useful for enhancing protection against a number of different infections.

13 Dec 2011

ISIS-FXIRx reduces Factor XI activity without bleeding in healthy volunteers

Isis Pharmaceuticals, Inc. announced today positive results from a Phase 1 study with ISIS-FXIRx. The results demonstrated that treatment with ISIS-FXIRx produced dose-dependent statistically significant reductions of up to 78 percent in Factor XI activity.

13 Dec 2011

Scientists create antigenic myeloma peptide 'cocktail'

Scientists at Dana-Farber Cancer Institute have created a "cocktail" of immune-stimulating peptides they believe could provoke the body's defenses to attack multiple myeloma in its early "smoldering" phase and slow or prevent the blood cancer.

13 Dec 2011

No change toward more aggressive biopsy follow-up of PSA tests, finds study

After the US Prostate Cancer Prevention Trial found cancer in many men with low levels of prostate specific antigen (PSA), many debated which PSA level should lead to a biopsy recommendation. The US Preventive Screening Task Force (USPSTF) recently concluded, amid considerable controversy, that the evidence does not support recommending PSA screening for men under 75 years old at all, because the risks outweigh the benefits.

13 Dec 2011